Matthew T. Gettman, M.D.

The study will be performed in two phases:  Phase I will be performed for biologic validation of marker candidates from a discovery cohort and phase II will be performed to evaluate the discrimination (sensitivity/specificity) of best candidate markers when assayed from blood of cases with CAP and controls without history of cancer. 

The purpose of this study is to compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively and to identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer.

The purpose of this study is to determine the effectiveness and safety of applying platelet rich plasma to nerve bundles of patients who are undergoing radical prostate removal surgery to help the nerve bundles heal.

The purpose of this study is to understand patient interest in use of wearable technology for monitoring health, assess patient willingness to use wearable device for healthcare monitoring, and to determine which wearable device that patients would prefer most.

The purpose of this study is to identify DNA methylation (genetic) markers in non-cancerous prostate tissue, and compare with the markers previously found to be in prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.

The purpose of this study is to evaluate the feasibility of perioperative electronic physical activity monitor use in a surgical population.

The objective of this study is to compare perioperative and oncologic outcomes of patients undergoing open and robotic prostatectomy for prostate cancer.

The purpose of this study is to see if the Uroflow Trace (r) mobile application provides an accurate representation of urinary flow tracing by comparing it to a clinical device used daily in the clinic.